Previous Article | Next Article ![]()
Eukaryotic Cell, December 2006, p. 2104-2113, Vol. 5, No. 12
1535-9778/06/$08.00+0 doi:10.1128/EC.00347-05
Copyright © 2006, American Society for Microbiology. All Rights Reserved.
Department of Biological Chemistry, University of Michigan Medical Center, Ann Arbor, Michigan 48109-0606
Received 16 November 2005/ Accepted 29 September 2006
|
|
|---|
|
|
|---|
-factor and other proproteins in the secretory pathway of the budding yeast Saccharomyces cerevisiae (11). Steady-state localization of Kex2p to the trans-Golgi network (TGN) depends on cycling of the protein between the TGN and the late endosome/prevacuolar compartment (PVC) (6). Kex2p localization is mediated by two TGN localization signals (TLSs) in the Kex2p cytosolic tail (6, 41). TLS1 promotes retrieval of Kex2p from the PVC to the TGN; whereas, TLS2 slows Kex2p delivery to the PVC, either through retention in the TGN or by promoting an alternative pathway through the early endosome (6, 15). Disruption of either TLS1 or TLS2 results in increased trafficking of Kex2p to the vacuole, where it is degraded (6, 41).
The SOI3 gene was identified by a mutation (soi3-1) that suppressed mislocalization of Kex2p bearing a Tyr713Ala mutation in TLS1 (27). Deletion of SOI3 disrupted trafficking of TGN membrane proteins Kex2p and A-ALP, a fusion protein consisting of the cytosolic domain of dipeptidyl aminopeptidase A fused to the transmembrane and lumenal domains of the vacuolar protein alkaline phosphatase (24) but not the vacuolar sorting receptor, Vps10p, between the TGN and PVC (34). The soi3
mutation also delayed delivery of the plasma membrane-localized a-factor receptor, Ste3p, to the vacuole at a step after endocytic internalization (34). Although most of the protein is cytosolic, a fraction of tagged Soi3p was associated with dense membranes and localized to peripheral punctate structures (34). These data argued that Soi3p is required for transport between the early endosome and PVC.
A clue to the molecular function of Soi3p in early endosome-to-PVC trafficking comes from the fact that the protein was independently isolated as Rav1p, a Skp1p-interacting protein that forms part of a complex termed RAVE (regulator of the H+-ATPase of the vacuolar and endosomal membranes), which includes a third polypeptide, Rav2p (33) (Soi3p will hereafter be referred to as Rav1p). RAVE is associated with the V1 subcomplex ("sector") of the vacuolar ATPase (V-ATPase), a multisubunit proton-translocating ATPase responsible for the acidification of intracellular compartments (13, 38). In yeast grown on a poor carbon source, V1 is largely cytosolic but can be induced, upon addition of glucose, to assemble with the integral membrane Vo sector to form an active holoenzyme (17). Rav1p is important for efficient assembly and for activation of V-ATPase (33, 36). We hypothesized that the role of Rav1p in early endosome-to-PVC transport reflects a requirement for assembly and activation of V-ATPase at the early endosome (34). This may be a conserved function in that V-ATPase activity is required for early endosome maturation in mammalian cells (8) and Rav1p has homologues in both Drosophila and humans (18, 19).
The Rav1p-Skp1 interaction is intriguing because Skp1p is a component of SCF (Skp1, Cdc53/Cullin, F-box protein)-type E3 ubiquitin-protein ligases. SCF complexes are responsible for ubiquitination of numerous substrates (10). The specificity of SCF complexes is achieved, in part, through the interchangeable F-box proteins that contain a Skp1p-binding motif (the F-box sequence) and a substrate recognition domain often consisting of WD-40 or leucine-rich repeats. The F-box protein thus acts as an adaptor between the ubiquitin transferase and its substrate (25). Although not an identified F-box protein, Rav1p does contain potential F-box motifs. Rav1p and the RAVE complex are hypothesized to be a non-SCF complex since additional components of the SCF complex cannot be coimmunoprecipitated (33).
Here we demonstrate that overexpression of Rav1p is toxic and that Skp1p acts as a multicopy suppressor of this toxicity. Taking advantage of the Rav1p overexpression phenotype, we designed a screen to identify skp1 mutants that would not interact with Rav1p but would maintain other essential interactions. One such mutant completely abrogated the Rav1p interaction and allowed us to dissect the role of the Rav1p-Skp1p interaction in Kex2p trafficking and V-ATPase assembly. We determined that the Rav1p-Skp1p interaction is not required for V-ATPase assembly/activation. Moreover, loss of the interaction alters Kex2p trafficking, but it does so differently than a rav1-null mutation. Finally, we found that loss of Skp1p-Rav1p binding alters localization of a Rav1-green fluorescent protein (GFP) fusion, suggesting that Skp1p functions in release of Rav1p from early endosomes.
|
|
|---|
Plasmids and strains are outlined in Tables 1 and 2. Plasmid pSOI3.HA.HIS6-SL was created by replacing the SacI site in pSOI3.HA.HIS6, in which sequences encoding a triple hemagglutinin (HA) epitope tag followed by six His codons are fused to the 3' end of the wild-type RAV1 gene (34), with a SalI site by linker ligation. Plasmid p413.ADH.SOI3.HA.HIS6, in which the RAV1 fusion is under the control of the ADH1 promoter on CEN6 ARS4 HIS3 plasmid p413 (22), was created by ligating the NarI/SalI fragment of pSOI3.HA.HIS6 containing the C terminus of SOI3.HA.HIS6 into p413ADH.SOI3 cleaved by NarI and SalI. Plasmid p416.ADH.SOI3.GFP was created by inserting an EcoRI/SalI fragment containing the SOI3.GFP fragment from p413.ADH.SOI3.GFP (34) into plasmid p416.ADH cleaved by EcoRI and SalI. Plasmid p413GAL.SOI3 was constructed by PCR amplifying the RAV1 structural gene with primers containing EcoRI sites and inserting the resulting fragment into the EcoRI site of p413.GAL.
|
View this table: [in a new window] |
TABLE 1. Yeast strains
|
|
View this table: [in a new window] |
TABLE 2. Plasmids
|
Identification of Skp1p and isolation of skp1(Asn108Tyr). EBY23 was transformed with a multicopy YEp13 library (42) and plated on SGC-Leu plates after a 4-h outgrowth in YPAD media. Transformants that grew on galactose-containing plates were isolated, and the resulting plasmids were retested for suppression of the toxicity of Rav1p overexpression. Inserts of confirmed suppressor plasmids were partially sequenced to identify the genomic insert.
A library of SKP1 mutants was created by PCR mutagenesis of wild-type SKP1 in plasmid pCB6 (4). Plasmid pCB6-XhoI
was created by digesting pCB6 with XhoI and blunting the ends with Klenow polymerase before ligation. Taq polymerase was used under standard conditions to maximize the yield of single-point mutations. Mutagenized PCR products were cotransformed into EBY23 along with pCB6-XhoI
, digested with AvaI/NsiI, to generate pCB6 containing mutagenized SKP1 inserts by homologous recombination. Transformants were plated on SGC-Leu plates after a 4-h outgrowth in liquid YPAD medium. Suppressors of Rav1p toxicity were isolated, and the phenotypes were confirmed. Confirmed plasmids were sequenced to identify the mutations.
Rav1p-Skp1p coimmunoprecipitation.
Cell extracts were prepared by gentle freeze-thaw lysis of yeast spheroplasts as described by Baker et al. and Sipos and Fuller (5, 35). S13 fractions were obtained from the supernatant by centrifugation of thawed spheroplasts, diluted in 800 µl of immunoprecipitation buffer containing protease inhibitors (50 mM Tris-HCl, pH 7.5, 100 mM NaCl, 0.1 mM EDTA, 0.1% Triton X-100, and Complete Mini protease inhibitor cocktail tablets [Roche]), at 13,000 x g for 5 min at 4°C. Extracts from 10 optical densities (OD) of cells (equivalent to 10 ml of cells grown in log phase to an A600 of 1.0;
1 x 108 cells) were immunoprecipitated with 0.25 µl of 12CA5 (5 mg/ml, anti-HA from Roche), 2 µl of rabbit anti-mouse (2 mg/ml; Jackson Laboratory), and 10 µl of Pansorbin (Calbiochem) for 2 h at 4°C. Immunoprecipitates were washed three times with immunoprecipitation buffer. Samples were fractionated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE, 11%), and gels were subsequently blotted to nitrocellulose (175 mA, 2 h). Nitrocellulose filters, probed with either anti-HA (1:5,000, 12CA5 from Roche) and sheep anti-mouse horseradish peroxidase (HRP, 1:2,000; Amersham) or rabbit anti-Skp1p antiserum (1:2,500; gift of Stephen Elledge, Harvard University) and protein A-HRP (1:5,000; Zymed), were developed using the ECL plus kit (Amersham).
Membrane fractionation. Cell extracts were prepared as described above except that thawed spheroplasts were homogenized with 15 strokes in a Dounce homogenizer prior to centrifugation. Sucrose gradients contained steps of 750 µl of 60% sucrose (in 20 mM Na-HEPES, pH 6.8) and 750 µl of 15% sucrose (in 20 mM Na-HEPES, pH 6.8) in 11- by 34-mm polyallomer centrifuge tubes (Beckman). S13 fractions from 125 OD of cells were loaded onto gradients and centrifuged at 200,000 x g for 4 h using a TLX centrifuge and TLS-55 swinging bucket rotor (Beckman). Membranes were collected from the interface of the two steps. S13 fractions were not examined because Rav1-HAp was unstable in this fraction (E. J. Brace and R. S. Fuller, unpublished data). The Golgi protein Mnn1p was used as a loading control (29). Membranes from 3.3 OD of cells were subjected to SDS-PAGE (8%), and gels were blotted to nitrocellulose (200 mA, 2 h). Blots were probed with either mouse monoclonal anti-GFP (1:100; Clontech) and sheep anti-mouse HRP (1:2,000; Amersham) or rabbit anti-Mnn1p (1:500; gift of Todd Graham, Vanderbilt University) and donkey anti-rabbit HRP (1:2,000; Amersham).
Microscopy. Microscopy was performed using a Nikon Eclipse 800 microscope and an ORCA2 charge-coupled device camera (Hamamatsu). ESEE Software (Inovision, Raleigh, NC) was used for image capture. Soi3-GFP images were from cells grown in log phase in minimal medium at 25°C. Quinacrine staining of yeast vacuoles was as described previously (30).
|
|
|---|
![]() View larger version (39K): [in a new window] |
FIG. 1. Overexpression of Rav1p is toxic. (A and B) CRY1 (wild type) cells were transformed either with p413GAL or p413GAL.RAV1, and GSY11-1A (rav1 ) was transformed with p413GAL. The p413GAL plasmid possesses the galactose-inducible GAL1 promoter. Strains were tested on SC-His (glucose) and SGC-His (galactose) for the ability to grow when Rav1p was overexpressed. (C) CRY1 (wild type) cells transformed with p413GAL.RAV1 were grown in log phase in either SSC-His (Sucrose) or SGC-His (galactose). Strains were visualized under differential interference contrast microscopy after 24 h.
|
![]() View larger version (31K): [in a new window] |
FIG. 2. Overexpression of Skp1p suppresses Rav1p toxicity. (A and B) CRY1 cells (wild type) were transformed with a YEp13 plasmid (2µm plasmid marked by LEU2), and EBY23 cells (integrated GAL.RAV1) were transformed with either the YEp13 plasmid or one of the isolated YEp13 library plasmids containing SKP1 (YEp13-SKP1, "2µ SKP1" in figure). Cells were grown on YPD (glucose) or YPG (galactose) to demonstrate that Skp1p is a multicopy suppressor of Rav1p overexpression.
|
The skp1(Asn108Tyr) mutant performs essential functions of Skp1p but does not bind Rav1p. To characterize specifically the role of Skp1p in Rav1p function, we screened for skp1 mutants that provided resistance to Rav1p overexpression but could support yeast cell growth. Presumably, such mutants would fail to bind Rav1p but would retain the ability to interact with other essential F-box proteins. After PCR mutagenesis, a single skp1 allele was identified that suppressed the toxic phenotype of Rav1p overexpression and could support growth in single copy in the absence of wild-type SKP1. The mutant, skp1(Asn108Tyr), was phenotypically distinct from other characterized skp1 point mutations (skp1-1, -2, -3, -11, and -12) (4, 9) in that none of these suppressed Rav1p overexpression at 25°C, 30°C, or 33°C (E. J. Brace and R. S. Fuller, unpublished data).
To determine directly whether the Rav1p-Skp1p interaction was disrupted by the skp1(Asn108Tyr) mutation, the ability of Rav1p to interact with Skp1p(Asn108Tyr) was tested by coimmunoprecipitation. Protein extracts of strains expressing Rav1-HAp and either Skp1p or Skp1p(Asn108Tyr) were immunoprecipitated with anti-HA under native conditions and probed with either anti-HA or anti-Skp1 antibodies. Rav1-HA coimmunoprecipitated wild-type Skp1p, but not Skp1p(Asn108Tyr) (Fig. 3B). This result confirmed that Skp1(Asn108Tyr) did not interact with Rav1p and supports both the conclusion that toxicity of Rav1p overexpression is caused by titration of Skp1p and that the Skp1p-Rav1p interaction is direct. Furthermore, because the allele could support growth as the lone copy of SKP1 (Fig. 3A, top), the essential interactions of Skp1p must remain intact.
![]() View larger version (38K): [in a new window] |
FIG. 3. Skp1p(Asn108Tyr) performs essential functions of Skp1p but does not bind Rav1p. A skp1 mutant [skp1(Asn108Tyr)] was identified through a genetic screen that suppressed the toxicity of Rav1p overexpression. (A) CRY1 (wild type), EBY23 (GAL.RAV1), GSY11-1A (rav1 ), EBY23 [pskp1(Asn108Tyr)], and EBY116-6 (skp1 ) [pskp1(Asn108Tyr)] were streaked out on YPD (glucose) and YPG (galactose) plates, demonstrating that skp1(Asn108Tyr) can both suppress Rav1p overexpression and exist as the sole copy of Skp1p in the cell. (B) Rav1p does not coimmunoprecipitate Skp1p(Asn108Tyr). Strains LPY01-4 {rav1 skp1 [pskp1(Asn108Tyr)]} and LPY02-4 (rav1 skp1 [pCB6]) were transformed with p413.ADH.RAV1.HA.HIS6 or p413.ADH.RAV1. The strains were grown at 25°C, and 10 ODs of S13 extract from yeast spheroplasts were immunoprecipitated under native conditions with 12CA5 antibody (anti-HA). Immunoprecipitations were separated on SDS-PAGE and transferred to nitrocellulose where they were probed with anti-HA (12CA5) or anti-Skp1 antibody to characterize the extent of Rav1p-Skp1 interactions. (C) The crystal structure of the mammalian Skp1-Skp2 complex is depicted with the skp1(Asn108Tyr) mutation Asn108Tyr modeled (Skp1, magenta; leucine-rich repeats of Skp2, blue; F-box of Skp2, green; Skp2-Leu116, yellow; Skp1-Asn108, red) (32). Graphic representation was made using MacPyMol (DeLano Scientific, LLC).
|
skp1(Asn108Tyr) does not affect V-ATPase function.
The skp1(Asn108Tyr) allele made it possible to determine whether the Skp1p-Rav1p interaction is important for V-ATPase assembly and activity. Mutations in V-ATPase subunit genes, such as VMA2, which encodes the B subunit of the ATPase hexamer, result in growth that is sensitive to high pH, zinc, and cobalt (3, 23) (E. J. Brace and R. S. Fuller, unpublished data). rav1 mutants, which are defective in ATPase assembly/activation, exhibit similar phenotypes (33, 34, 36). As shown in Fig. 4A and B, whereas vma2
and rav1
strains grew at pH 5.6 but not at pH 7.5, the skp1(Asn108Tyr) strain grew well at both low and high pH. Also, unlike rav1
and vma2
mutants, the skp1(Asn108Tyr) mutant did not show sensitivity to 5 mM ZnCl2 or 750 µM CoCl2 (Fig. 4C and D). V-ATPase and rav1
mutants are defective for vacuolar accumulation of the fluorescent dye quinacrine (33, 36). In contrast, the skp1(Asn108Tyr) strain exhibited normal quinacrine accumulation (Fig. 4E). These results demonstrate that binding of Skp1p to Rav1p is not required for V-ATPase assembly/activation.
![]() View larger version (37K): [in a new window] |
FIG. 4. skp1(Asn108Tyr) does not affect V-ATPase function. (A to D) Serial dilutions of strains CRY2 (wild type), GSY11-2A (rav1 ), EBY72-2 (vma2 ), and EBY116-6 [skp1 pskp1(Asn108Tyr)] were pronged onto the indicated media and incubated for 2 days. (A and B) YPAD plates, pH 5.6 or pH 7.5, grown at 37°C; (C) YPAD with 5 mM ZnCl2 (pH 5.6) grown at 30°C; (D) YPAD with 750 µM CoCl2 at 30°C. (E) Strains CRY2 (wild type), GSY11-2A (rav1 ), and EBY116-6 [skp1 pskp1(Asn108Tyr)] were tested for their ability to accumulate quinacrine in their vacuoles. Cells were allowed to accumulate quinacrine for 10 min at 30°C and cooled on ice for 5 min. Cells were then visualized immediately by differential interference contrast and fluorescence microscopy.
|
alter Kex2p trafficking in distinct ways.
rav1
mutants exhibit defects in the trafficking of Kex2p between the early endosome and PVC (34). The effect of rav1
or other mutations on Kex2p localization can be monitored in vivo using the "onset of impotence" assay (27). Mislocalization of Kex2p disrupts processing of pro-
-factor and thus impairs production of the peptide mating pheromone
-factor, which is required for mating. When Kex2p expression, under control of the glucose-repressible GAL1 promoter, is shut off by shifting cells to glucose medium, the rate of loss of mating competence over time reflects the loss of preexisting enzyme from the pro-
-factor processing compartment (Fig. 5A). A Y713A mutation in TLS1 in the Kex2p cytosolic tail causes more rapid loss of mating competence because of failure to retrieve Kex2p from the PVC to the TGN. Loss of TLS2 function results in more rapid loss of mating competence because of increased transport to the PVC (6).
![]() View larger version (32K): [in a new window] |
FIG. 5. Skp1p affects trafficking of Kex2p. (A) Model of TLS1 and TLS2 function in Kex2p trafficking between the TGN and endosomal system. (B) Strains KRY18-1A (kex2 ), GSY11-r1 (kex2 rav1 ), and EBY127-2 [kex2 skp1 pskp1(Asn108Tyr)] were transformed with pCWKX20 (GAL1-KEX2; wild type [WT]), pCWKX21 (GAL1-KEX2 Y713A; TLS1), pCWKX20-I718tail (GAL1-KEX2-I718 tail; TLS2), and pCWKX21-I718tail (GAL1-KEX2 Y713A-I718 tail; TLS1 TLS2). Strains were grown at 25°C, shifted from galactose to glucose medium for the indicated times, and assessed for mating competence as described previously (27).
|
mutation with all forms of Kex2p tested (Fig. 5B). Whereas the rav1
mutation suppressed effects of both the TLS1 mutation alone and in combination with the TLS2 mutation, the skp1(Asn108Tyr) mutation did not. The skp1(Asn108Tyr) mutation did have effects in the assay, causing more rapid loss of mating competence compared to the wild-type strain background with wild-type (by 10 h) (Fig. 5B, top panel) and TLS2 mutant (by 6 h) (Fig. 5B, third panel) Kex2p and had a slight effect on TLS1 mutant Kex2p (Fig. 5B, second panel). These effects of the skp1(Asn108Tyr) allele were not due to general defects in mating because the skp1(Asn108Tyr) mutant demonstrated mating indistinct from wild-type strains in a quantitative mating assay (E. J. Brace and R. S. Fuller, unpublished data). Paradoxically, skp1(Asn108Tyr) improved mating over time with the TLS1 TLS2 double mutant (Fig. 5B, bottom panel). Although the effects of skp1(Asn108Tyr) in this assay are complex, the key result, that the skp1(Asn108Tyr) and rav1
mutants behave differently, is completely consistent with the conclusion reached above that the Skp1p-Rav1p interaction is not required for the function of Rav1p in V-ATPase assembly/activation.
Of note, the skp1(Asn108Tyr) mutation did not disrupt either the trafficking of the vacuolar protein sorting receptor, Vps10p, as measured by secretion of carboxypeptidase Y or endocytosis, as measured by FM4-64 uptake (E. J. Brace and R. S. Fuller, unpublished results). This points out one similarity between the rav1
and skp1(Asn108Tyr) mutations: both affect Kex2p but not Vps10p trafficking. This may reflect the fact that Kex2p reaches the PVC both by direct TGN-PVC transport and by trafficking through the early endosome, whereas Vps10p follows only the direct pathway (34).
Rav1-GFP is recruited to membranes in skp1(Asn108Tyr) and doa4
mutants.
In yeast cells, Rav1p is present both in a soluble pool and as a peripheral protein associated with a high-density membrane compartment suggestive of early endosomes (34). The bulk of Rav1-GFP fluorescence was cytosolic, but image deconvolution made it possible to identify discrete Rav1-GFP puncta (34). The skp1(Asn108Tyr) mutant was examined to determine whether Skp1p affects recruitment of Rav1-GFP to membranes. Surprisingly, in the skp1(Asn108Tyr) mutant, Rav1-GFP localized more extensively to puncta that were visualized even without the aid of image deconvolution (Fig. 6A). To determine if total Rav1p protein levels were altered in the skp1(Asn108Tyr) or doa4
mutants, Rav1-GFP levels were determined by Western blotting (L. P. Parkinson and R. S. Fuller, unpublished results). Rav1-GFPp levels were unchanged in the skp1(Asn108Tyr) mutant but were slightly lower in the doa4
mutant. The latter effect may account for the lower cytosolic Rav1-GFP fluorescence seen in the doa4
strain. These data suggest that Rav1-GFP accumulation on membranes is not due to increased levels of Rav1-GFP protein but is due to altered localization of the protein. Sucrose step gradients were used to provide an alternative way of assessing Rav1-GFP localization to membranes in the skp1(Asn108Tyr) background. S13 fractions (13,000 x g supernatant) of yeast extracts were further fractionated by equilibrium centrifugation at 200,000 x g using a two-step sucrose gradient. Samples were tested for the accumulation of Rav1-GFP at the 15%-60% sucrose interface that separates membrane fractions from large protein complexes that pellet and cytosolic proteins that sediment slowly and fractionate above the 15% step. Rav1-GFP more readily accumulated at the 15%-60% interface of the gradient in a skp1(Asn108Tyr) mutant, suggesting that the mutant is defective in releasing Rav1p from membranes (Fig. 6B).
![]() View larger version (24K): [in a new window] |
FIG. 6. Rav1-GFP is localized to membranes in mutants. (A) Strains GSY11-2A (rav1 ), EBY116-4 [rav1 skp1 skp1(Asn108Tyr)], EBY79-12 (rav1 doa4 ), and EBY79-12 (YEp96; wild-type [WT] ubiquitin) were transformed with p416.ADH.RAV1-GFP. For simplicity, the rav1 is not marked on the figure, since it is covered by the RAV1 plasmid. Strains were grown at 25°C in minimal media (including 100 µM CuSO4 for the ubiquitin experiment) and maintained in log phase. Differential interference contrast and fluorescence microscopy were performed using an E800 Nikon microscope and ISEE digital imaging software. All images were obtained with the same exposure times and gain. Punctate staining can be seen in each of the mutants pictured (white arrowheads). (B) Rav1-GFP accumulates in the membrane fraction. Strains GSY11-1A (rav1 ), EBY116-4 [rav1 skp1 pskp1(Asn108Tyr)], EBY79-11 (rav1 doa4 ), and EBY79-11 (rav1 doa4 pYEp96) were transformed with p416ADH.RAV1-GFP. S13 was created from 125 ODs of yeast spheroplasts and loaded on top of a sucrose step gradient consisting of 15% and 60% layers. To measure Rav1-GFP localization to membranes, membrane fractions were collected at the 15 to 60% interface and separated by SDS-PAGE before being transferred to nitrocellulose. Rav1-GFP was not visible in whole-cell extracts because of apparent degradation. The nitrocellulose was probed with anti-GFP or anti-Mnn1p, which was used as a loading control.
|
mutant to determine if Rav1p localization depended on ubiquitin. Indeed, Rav1-GFP demonstrated increased membrane localization in a doa4
mutant, as shown both by fluorescence microscopy and by the sucrose step gradient fractionation (Fig. 6A and B). However, ubiquitin overexpression did not rescue the effect of the doa4
mutant, suggesting that Doa4p may be directly involved in Rav1p localization. |
|
|---|
Surprisingly, the skp1(Asn108Tyr) mutant exhibited phenotypes that were distinct from those of both rav1
and vma2
mutants, suggesting that the Skp1p-Rav1p interaction is not essential for the function of Rav1p in V-ATPase assembly/activation. Unlike rav1
and vma2
mutants, the skp1(Asn108Tyr) mutant exhibited no defects in quinacrine accumulation in the vacuole or in growth on zinc-containing, cobalt-containing, or high-pH media. In a previous study, the temperature-sensitive skp1-12 mutant exhibited growth that was sensitive to high pH as well as a defect in vacuolar quinacrine accumulation (33). However, skp1-12 did not suppress Rav1p overexpression (E. J. Brace and R. S. Fuller, unpublished data), suggesting that the Skp1p-Rav1p interaction is not disrupted by skp1-12. The effects of the skp1-12 mutation may therefore be indirect, resulting from the nonspecific nature of the allele. skp1-12 was identified as a mutant that caused temperature sensitivity for growth and which, therefore, disrupted at least one essential Skp1p function (4). In contrast, the skp1(Asn108Tyr) mutant specifically disrupts the Skp1p-Rav1p interaction but leaves intact the Skp1p interactions that are essential for growth. Synthesis of these findings suggests that the skp1-12 mutation may affect pH sensitivity and quinacrine accumulation not by loss of the specific Skp1p-Rav1p interaction but by loss of one or more other Skp1p interactions. We conclude, therefore, that the Skp1p-Rav1p interaction is not required for V-ATPase assembly/activation. A second line of evidence that Skp1p function is distinct from that of Rav1p is the fact that although the skp1(Asn108Tyr) mutation did alter Kex2p localization, as judged by the onset of impotence assay, the effects were quite different than those of the rav1
mutation. The effects of the skp1(Asn108Tyr) allele may be a consequence of alterations in Rav1p localization.
Whereas skp1(Asn108Tyr) did not affect Rav1p function in V-ATPase assembly and activation, it did have a clear effect on Rav1p localization. In contrast to wild-type cells, in the skp1(Asn108Tyr) mutant, Rav1-GFP was readily apparent in cytoplasmic puncta even without image deconvolution, presumably reflecting both an increase in membrane localization and a decrease in the cytosolic pool. Increased membrane localization was confirmed by biochemical fractionation. Interestingly, although Rav1-GFP showed increased localization to membranes in the skp1(Asn108Tyr) mutant, microscopic examination showed that sites of localization corresponded to punctate organelles rather than to vacuolar membranes. This is consistent with the proposed role for the RAVE complex in V-ATPase assembly/activation at the early endosome (34). A link between the roles of Rav1p in trafficking and V-ATPase activity is suggested by the fact that bafilomycin A1, a potent and specific inhibitor of V-ATPase, disrupts traffic between the early and late endosome in mammalian cells (8). Mutations in V-ATPase cause defects in the internalization of the fluorescent dye FM4-64 from the plasma membrane to the vacuole in yeast (26). Additionally, V-ATPase mutants exhibit defects in Kex2p trafficking (E. J. Brace and R. S. Fuller, unpublished data).
Loss of Doa4p also resulted in increased membrane association and punctate localization of Rav1-GFP. Because this effect was not overcome by ubiquitin overexpression, it was not an indirect result of ubiquitin depletion in the cells. These results suggest that both the Skp1p interaction with Rav1p and a deubiquitination event mediated by Doa4p are required for release of Rav1p from endosomal membranes. Although the RAVE complex has been classified as a non-SCF type Skp1p complex because of the absence of Cdc53p, Rbx1p, and Cdc34p (33), an intriguing but highly speculative possibility is that Skp1p may participate transiently in a ubiqitination reaction that is important for release of the RAVE complex from endosomal membranes. In this view, Skp1p and Doa4p might be required for a cycle of ubiquitination and deubiquitination that regulate Rav1p association with the endosomal compartment.
There are two other known Skp1p-containing non-SCF complexes in yeast, the Rcy1p-Skp1p complex (12) and the kinetochore complex CBF3 (9). Notably, the F-box protein Rcy1p functions at the early endosome to regulate recycling of internalized proteins from the cell surface (12, 20, 40). Mutations in RCY1 have recently been shown to affect Kex2p trafficking (7). Rav1p and Rcy1p may govern distinct pathways out of the early endosome. Thus, it is plausible that Skp1p may function as a regulator of both processes.
This work was supported in part by NIH grants GM50915 and GM39697 to R.S.F. and P30 CA46592 to the University of Michigan Comprehensive Cancer Center.
Published ahead of print on 13 October 2006. ![]()
|
|
|---|
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Copyright © 2009 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»